The author replies

New England Journal of Medicine

Volumn 373, Issue 5, 2015, Pages 485-486

  Camaschella, Clara ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IRON;

DRUG EFFICACY; HUMAN; IRON DEFICIENCY ANEMIA; IRON THERAPY; LETTER; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL; TREATMENT OUTCOME; METABOLISM;

ANEMIA, IRON-DEFICIENCY; HUMANS; IRON;

EID: 84938363543     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1507104     Document Type: Letter

References (5)

1. Carson JL, Adamson JW. Iron deficiency and heart disease: ironclad evidence? Hematology Am Soc Hematol Educ Program 2010;2010:348-50.
2. Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:2436-48.
3. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 2015;36:657-68.
4. Krayenbuehl PA, Battegay E, Breymann C, Furrer J, Schulthess G. Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood 2011;118:3222-7.
5. Pasricha SR, Low M, Thompson J, Farrell A, De-Regil LM. Iron supplementation benefits physical performance in women of reproductive age: a systematic review and meta-analysis. J Nutr 2014;144:906-14.